Allergy Therapeutics said will present 18 posters and host two symposia at the European Academy of Allergy and Clinical Immunology (EAACI) 2022 this month.
These will include further data from preclinical studies demonstrating the potential of its peanut allergy vaccine candidate (VLP Peanut); detailed findings from the hay fever vaccine G309 exploratory field study; and preclinical and clinical studies examining the effect on pollen and dust mite allergies of immunoBON, the group's micro-nutrition FSMP (Food for Special Medical Purpose).
Manuel Llobet, chief executive, said: "Allergy Therapeutics is committed to developing novel, short-course allergy immunotherapies to transform patients' lives.
"With a strong presence at this year's EAACI congress, where we are presenting 18 posters and hosting two symposia, we are demonstrating the strength of our science and our commitment to continued innovation.
“Our latest findings pave the way for the initiation of two key clinical trials later this year - a Phase III trial of our short-course grass pollen immunotherapy candidate, Grass MATA MPL, and the Phase I PROTECT trial of our peanut allergy vaccine candidate, VLP Peanut."